جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

19 مُخرَج نتائج البحث عن «Randomized controlled trial»

مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Therapeutic Efficacy and Safety of Botulinum Toxin Type A in Erythematotelangiectatic Rosacea: A Systematic Review

Cureus · مجلد 18 (4) · e106841-e106841

Botulinum toxin type A (BoNT-A) injections have a well-known cosmetic outcome and safety profile in a variety of medical conditions. Recent studies have shown promising results for possible use in treating erythematotelangiectatic rosacea (ETR). This systematic review aimed to evaluate the efficacy and safety of BoNT-A injections in patients with ETR. A systematic search was conducted across multiple databases to identify relevant studies. Eligible articles were randomized controlled trials (RCTs) that investigated BoNT-A injections in adults diagnosed with ETR. Studies involving other rosacea subtypes, lacking a comparative group, or combining BoNT-A with other interventions without isolating its effects were excluded. Three RCTs met the inclusion criteria. Both parallel-group and split-face analyses demonstrated that BoNT-A injections significantly reduced facial erythema and flushing, resulting in improved patient satisfaction. Across all studies, BoNT-A was well-tolerated, with adverse events being mild, transient, and self-limited. However, the evidence remains limited by the small sample sizes, suboptimal study designs, and short follow-up durations. BoNT-A injections show promising efficacy and safety in the treatment of ETR. However, larger, well-designed randomized trials with longer follow-up durations are required to confirm its therapeutic role and establish standardized treatment protocols.

botulinum toxin type Aerythematotelangiectatic rosaceafacial erythemaflushing
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (3) · e106154-e106154

Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.

melasmalaser therapyQ-switched Nd:YAG laserpicosecond laser
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (2) · e103029-e103029

Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.

ACE inhibitorsangiotensin receptor blockerstype 2 diabetesrenin-angiotensin-aldosterone system blockade
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Efficacy of Selective Serotonin Reuptake Inhibitors for the Treatment of Chronic Pain and Comorbid Depression in Individuals With Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (2) · e102998-e102998

Fibromyalgia causes symptoms like chronic widespread pain, fatigue, and cognitive difficulties, often alongside depression and chronic pain, complicating treatment. While selective serotonin reuptake inhibitors (SSRIs) are prescribed for fibromyalgia-related depression and pain, their effectiveness is unclear. This systematic review and meta-analysis evaluated SSRI efficacy in fibromyalgia patients with comorbid depression and chronic pain. This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid, and Google Scholar. We included randomized controlled trials (RCTs) using formal fibromyalgia criteria and reporting depression or pain outcomes. Non-RCTs, studies with non-adults, or non-SSRI comparisons without isolating SSRI effects were excluded. The Cochrane risk-of-bias tool for randomized trials (RoB-2) was used to assess the risk of bias in this study. Four reviewers independently screened titles and abstracts; four assessed full-texts with disagreements resolved by a senior reviewer. Outcome data were converted to mean change scores from baseline where not directly reported. The standardized mean difference (SMD) was used for the meta-analysis to pool data across different scales. Nine RCTs (n = 461 participants, predominantly female, mean ages across studies ranged from 32.7 to 52.9 years) were analyzed. Compared to placebo, SSRIs significantly reduced pain (eight RCTs, n = 421; SMD -0.53, 95% confidence interval (CI): -0.92 to -0.14, p = 0.007) and improved depression (six RCTs, n = 265; SMD -0.67, 95% CI: -1.14 to -0.20, p = 0.005). SSRIs also significantly improved quality of life (QOL) versus placebo (five RCTs, n = 301; SMD -0.30, 95% CI: -0.55 to -0.04, p = 0.02). Compared to other non-pharmacological interventions (acupuncture and aerobic exercise), SSRIs showed non-significant improvement in depression (two RCTs, n = 70; SMD -0.39, 95% CI: -1.32 to 0.54, p = 0.41). Common side effects included gastrointestinal issues, dry mouth, sedation, sexual dysfunction, and headaches; SSRI groups reported more adverse events and higher dropout rates. SSRIs showed statistically significant benefits for pain, depression, and QOL in fibromyalgia compared to placebo. However, the overall evidence quality was found to be very low to low due to heterogeneity and risk of bias. Future RCT designs should adhere to a strict methodology in order to strengthen the available evidence on the efficacy of SSRIs in treating fibromyalgia.

fibromyalgiaselective serotonin reuptake inhibitorscomorbid depressionchronic widespread pain
مراجعةوصول مفتوح2026

Rifaximin Versus Placebo for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (9) · e116820-e116820

Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.

rifaximinirritable bowel syndromeplacebo comparisonantibiotic therapy
مراجعةوصول مفتوح2026

Post-acne Erythema: A Systematic Review of Randomized Controlled Trials on the Comparative Efficacy and Safety of Interventions Across Clinical, Instrumental, and Patient-Reported Outcomes

Cureus · مجلد 18 (9) · e116495-e116495

Post-acne erythema (PAE) is a persistent acne sequela without an established standard treatment. This systematic review evaluated the comparative efficacy and safety of interventions tested in randomized trials. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through August 1, 2026. Randomized parallel-group and split-face trials reporting erythema outcomes were eligible. Risk of bias was assessed with the Cochrane Risk of Bias 2 (RoB 2) tool. Heterogeneity precluded meta-analysis, and available findings were synthesized narratively. Nine trials involving 301 participants contributed 11 pairwise comparisons. Against untreated or blank controls, favorable effects were reported for picosecond alexandrite laser, narrow-spectrum vascular intense pulsed light (IPL), and non-cross-linked hyaluronic acid mesotherapy. A 577-nm semiconductor laser showed interim instrumental benefit, but blinded assessors found no final between-side difference. In active-treatment and add-on comparisons, narrow-spectrum IPL was favored over broad-spectrum IPL, neodymium-doped yttrium aluminum garnet (Nd) laser added to low-dose isotretinoin was favored over isotretinoin alone, and 577-nm pro-yellow laser was favored over topical brimonidine. Botulinum toxin type A was favored over broadband light at the earliest assessment only. Fractional laser and pulsed dye laser did not differ significantly, while delicate pulsed light and Q-switched 1064-nm Nd laser showed no sustained difference at the final assessment. Adverse events were mild and transient, although pigmentation and blistering occurred with one broad-spectrum IPL protocol. Five trials had some concerns, and four had high overall risk of bias. Trials suggested potential benefits, but small samples, heterogeneity, short follow-up, and reporting limitations precluded identification of a preferred treatment. Larger, prospectively registered trials using blinded assessment and standardized outcomes are needed.

intense pulsed lightNd:YAG laserisotretinoinbrimonidine
مراجعةوصول مفتوح2026

Comparative Effectiveness of Nonoperative Treatments for Acute Anterior Epistaxis in Emergency and Otolaryngology Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (8) · e115154-e115154

Acute anterior epistaxis is frequently managed with multiple nonoperative interventions, but comparative evidence regarding their effectiveness remains uncertain. This systematic review and meta-analysis evaluated the effectiveness and safety of nonoperative treatments for acute anterior epistaxis in emergency and otolaryngology settings. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception through 3 July 2026 for randomized controlled trials (RCTs) comparing nonoperative hemostatic interventions in adults with acute anterior epistaxis. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool, and random-effects meta-analysis was performed when sufficient clinical comparability was present. Nine RCTs including 1,124 participants were identified, with three trials contributing to quantitative synthesis. Topical tranexamic acid reduced rebleeding within 24 hours compared with matched vehicle controls (RR, 0.39; 95% CI, 0.17-0.89), with an absolute risk reduction of 19.1 percentage points. However, topical tranexamic acid was not associated with a significant reduction in further hemostatic intervention (RR, 0.59; 95% CI, 0.22-1.59). Other nonoperative strategies showed variable effects across heterogeneous outcomes. Overall, topical tranexamic acid may reduce early rebleeding in acute anterior epistaxis, but evidence regarding broader clinical outcomes remains limited by the small number of comparable trials, heterogeneous protocols, and inconsistent outcome definitions. Further high-quality randomized trials with standardized outcomes are required to clarify the optimal role of these interventions.

conservative treatmentepistaxis managementemergency department careotolaryngology practice
مراجعةوصول مفتوح2026

Comparison Between High-Flow Nasal Cannula (HFNC) Therapy and Noninvasive Ventilation (NIV) in Children With Bronchiolitis-Associated Acute Respiratory Failure: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (8) · e114308-e114308

The optimal noninvasive respiratory support for infants and children with severe viral bronchiolitis remains unclear. While continuous positive airway pressure (CPAP) has traditionally been considered the gold standard, high-flow nasal cannula (HFNC) therapy is a better-tolerated alternative. This systematic review and meta-analysis aimed to evaluate the comparative efficacy and safety of HFNC versus noninvasive ventilation (NIV) in pediatric patients with bronchiolitis-associated acute respiratory failure. We searched major electronic databases through June 2026. We included randomized controlled trials (RCTs) and observational cohorts comparing HFNC with NIV (CPAP/bilevel positive airway pressure (BiPAP)). The primary outcomes were treatment failure, as defined by the individual studies, and endotracheal intubation. Data were synthesized using random-effects models, and heterogeneity was explored via subgroup analysis and meta-regression. Eleven studies (seven RCTs and four observational studies) comprising 7,574 patients were included. There was no statistically significant difference in the overall risk of treatment failure between HFNC and NIV (RR 1.99, 95% CI 0.65-6.10); however, study design was a significant moderator (p = 0.0019). Observational studies reported significantly higher failure rates with HFNC (RR 7.78), whereas RCTs showed no significant difference (RR 1.11). There were no significant differences in endotracheal intubation rates (RR 0.75, 95% CI 0.51-1.09) or pediatric intensive care unit length of stay (MD -0.16 days, 95% CI -0.79 to 0.47) between the groups. HFNC demonstrated a trend toward fewer local adverse events, such as nasal/skin trauma (RR 0.30, 95% CI 0.06-1.52), than did NIV. The certainty of evidence according to GRADE was low for all outcomes. HFNC showed no significant differences from NIV in critical clinical endpoints, including intubation rates and intensive care duration. Differences in treatment failure rates appeared to be influenced by study design, highlighting potential confounding by indication in observational data. Given its improved tolerability and trend toward reduced mucosal trauma, HFNC may represent a viable first-line noninvasive intervention for pediatric bronchiolitis.

high-flow nasal cannulanon-invasive ventilationpediatric bronchiolitisacute respiratory failure
مراجعةوصول مفتوح2026

Comparative Effectiveness of Antihypertensive Agents vs. Control in the Prevention and Management of Preeclampsia: A Network Meta-Analysis

Cureus · مجلد 18 (5) · e109602-e109602

Hypertensive disorders of pregnancy, particularly preeclampsia, are a leading cause of maternal and perinatal morbidity. While antihypertensive therapy is recommended, clinical uncertainty persists regarding the optimal agent to maximize maternal safety while minimizing adverse neonatal outcomes such as neonatal intensive care unit (NICU) admission. This review aimed to evaluate the comparative effectiveness and safety of pharmacological antihypertensive agents versus standard care or placebo in the management of hypertensive disorders of pregnancy through a network meta-analysis (NMA). A systematic review and frequentist random-effects NMA of randomized controlled trials (RCTs) was conducted. Major databases were searched for RCTs comparing antihypertensive agents (labetalol, nifedipine, methyldopa, hydralazine, prazosin) and controls. The primary neonatal outcome evaluated in this network was NICU admission. Risk of bias was assessed using the Cochrane RoB 2 tool, and the certainty of evidence was evaluated using the GRADE framework. Twenty-five RCTs were included in the qualitative and quantitative synthesis. The network geometry was anchored by labetalol and nifedipine. In the NMA, no individual antihypertensive agent demonstrated a statistically significant reduction in the risk of NICU admission compared to labetalol. However, probabilistic ranking (P-scores) identified methyldopa (P-score = 0.859) and hydralazine (0.791) as the most favourable interventions for minimizing NICU admissions. Nifedipine showed a slightly elevated, though non-significant, risk profile compared to labetalol (RR 1.09, 95% CI 0.80-1.49). The placebo and standard care ranked lowest. The overall certainty of evidence ranged from moderate to very low due to imprecision and indirectness. Active pharmacological management of hypertension in pregnancy is superior to placebo or standard care. While labetalol and nifedipine remain mainstays for acute blood pressure control, methyldopa and hydralazine probabilistically rank higher for minimizing NICU admissions. These findings support individualized antihypertensive selection based on clinical acuity and maternal-fetal hemodynamics.

preeclampsiahypertensive disorders of pregnancyantihypertensive drugslabetalol
مراجعةوصول مفتوح2026

Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review

Cureus · مجلد 18 (5) · e108953-e108953

Nail lichen planus (NLP) is a chronic immune-mediated inflammatory disorder and one of the most challenging forms of lichen planus to treat. Conventional therapies, including intralesional corticosteroids, systemic immunosuppressants, and topical agents, are often associated with high failure rates and significant adverse effects. Janus kinase inhibitors (JAKIs) have emerged as mechanistically rational therapeutic agents because of the central role of the interferon (IFN)-JAK-signal transducer and activator of transcription (JAK-STAT) pathway in lichenoid inflammation; however, their efficacy and safety in NLP have not yet been systematically evaluated. A systematic review was conducted by searching PubMed, Scopus, and Web of Science from database inception through March 2026 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Eligible studies included patients with clinically and/or histopathologically confirmed NLP and studies reporting original patient-level data of any design. Risk of bias was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools appropriate to each study design. A cumulative time-to-response model was constructed, and a random-effects meta-analysis of standardized mean change (SMC) in nail severity scores was performed where data permitted. Thirteen studies were included with a total of 25 patients. Interventions included oral and topical tofacitinib, baricitinib, abrocitinib, upadacitinib, and topical ruxolitinib. Clinically meaningful improvement was reported across all studies, with most responses occurring within three to seven months of treatment initiation. The pooled SMC was 1.65 (95% confidence interval (CI): 0-3.59), with substantial heterogeneity (I²=87.6%). No serious adverse events were reported. Overall, JAKIs appear to be effective and well tolerated in the short term for refractory NLP, supporting their potential role as rescue therapy in selected cases. However, the current evidence remains limited and heterogeneous, underscoring the need for prospective randomized controlled trials with standardized outcome measures and longer follow-up durations.

nail lichen planusJAK inhibitorsrefractory lichen planustofacitinib
مراجعةوصول مفتوح2026

Comparative Effectiveness of Internal Fixation Versus Hemiarthroplasty and Total Hip Arthroplasty for Displaced Femoral Neck Fractures in Patients Aged ≥65 Years: A Network Meta-Analysis

Cureus · مجلد 18 (4) · e107725-e107725

The ideal surgical approach for treating displaced femoral neck fractures (FNFs) in elderly patients is a clinical debate. While internal fixation (IF), hemiarthroplasty (HA), and total hip arthroplasty (THA) represent the established treatment methods, their relative hierarchy regarding safety and efficacy has not been fully established. This study aimed to evaluate and rank these interventions using a network meta-analysis (NMA) framework. MEDLINE, Embase, CENTRAL, Web of Science, and Scopus were searched for randomized controlled trials (RCTs) comparing IF, HA, and THA in patients aged ≥65 years with acute displaced FNFs. The primary outcomes were reoperation rate and all-cause mortality. Secondary outcomes included functional scores (Harris Hip Score (HHS)), quality of life, and dislocations. A frequentist, multivariate, random-effects NMA with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment was performed. The required information size (RIS) and evidence conclusiveness were evaluated using trial sequential analysis (TSA). A treatment hierarchy was established using the surface under the cumulative ranking (SUCRA) curve analysis. Seventeen RCTs (3,223 patients) were included. Arthroplasty significantly reduced the risk of reoperation compared to IF (THA: RR 0.18, 95% CI 0.07-0.44; HA: RR 0.35, 95% CI 0.16-0.76). TSA confirmed that the cumulative evidence for the superiority of THA over IF in reducing reoperation has reached conclusive thresholds. THA achieved the highest functional recovery at 24 months compared to IF (MD 9.73, 95% CI 6.67-12.79), surpassing the minimal clinically important difference (MCID). SUCRA rankings identified THA as the superior intervention for both reoperation prevention (97.2%) and functional efficacy (99.5%). No significant differences were observed in all-cause mortality across the network. Arthroplasty is superior to IF for displaced FNFs in older adults. THA provides the most robust reduction in reoperation risk and superior functional restoration. Although HA remains a viable alternative, IF should be avoided as a primary treatment in this population because of its high failure rate.

internal fixationhemiarthroplastytotal hip arthroplastyelderly patients
مراجعةوصول مفتوح20259استشهاد· Semantic Scholar

Minimally Invasive Approach Versus Traditional Approach for Treating Congenital Diaphragmatic Hernia: A Systematic Review and Meta-Analysis

Cureus · مجلد 17 (1) · e77596-e77596

Congenital diaphragmatic hernia (CDH) is a rare but critical surgical disorder that can be managed using either open or thoracoscopic surgical approaches. However, the optimal approach remains a topic of debate. This study aimed to evaluate the efficacy and safety of thoracoscopic repair compared to open repair in patients with CDH. An extensive literature search was conducted across four databases (PubMed, Web of Science, Scopus, and Cochrane Library) from inception to May 2024, including all relevant studies comparing the two surgical modalities. Key outcomes assessed were hospital stay duration, operation time, mortality, and recurrence. Categorical outcomes were analyzed using the risk ratio (RR) with 95% confidence intervals (CI), while continuous outcomes were analyzed using the mean difference (MD) with 95% CI. Data analysis was performed using Review Manager (RevMan, Version 5.3). A total of 35 studies involving 1,680 individuals with CDH were included in our analysis. The pooled results revealed that thoracoscopic repair was associated with a shorter hospital stay (MD=-6.80, 95% CI [-9.39, -4.21], p< 0.0001) but a longer operation time (MD=23.30, 95% CI [7.22, 39.38], p=0.005) compared to the open approach. Additionally, thoracoscopic repair demonstrated lower mortality rates (RR=0.43, 95% CI [0.24, 0.76], p=0.004) but higher recurrence rates (RR=2.24, 95% CI [1.56, 3.21], p<0.0001) than open repair. Our findings suggest that thoracoscopic repair offers shorter hospital stays and lower mortality rates but involves longer operation times and higher recurrence rates compared to the open approach. These results highlight the need for further large, multicenter, randomized controlled trials to validate our findings and guide clinical decision-making.

congenital diaphragmatic herniathoracoscopic repairopen surgical repairminimally invasive surgery
مراجعةوصول مفتوح20254استشهاد· Semantic Scholar

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Trials

Cureus · مجلد 17 (6) · e86232-e86232

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with type 2 diabetes mellitus (T2DM), contributing to increased liver-related complications and cardiovascular risk. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as potential treatments offering benefits for both metabolic and liver-related outcomes. This systematic review evaluated the efficacy of SGLT2 inhibitors in improving hepatic steatosis, liver enzymes, glycemic control, and liver histology in patients with T2DM and NAFLD. The review was conducted using a structured methodology, including systematic database searches and risk of bias assessments. Included randomized controlled trials (RCTs) investigated various SGLT2 inhibitors, such as dapagliflozin, empagliflozin, ertugliflozin, and ipragliflozin. Most studies showed significant reductions in liver fat content, improvements in serum liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT)), and favorable effects on blood pressure, triglycerides, and body composition. Glycemic control markers, including glycated hemoglobin (HbA1c), fasting glucose, and insulin resistance indices, also improved. One biopsy-based study demonstrated histological improvements, including reduced fibrosis and resolution of nonalcoholic steatohepatitis (NASH). No serious adverse events were reported. These findings suggest SGLT2 inhibitors may offer dual benefits for managing both diabetes and fatty liver disease. Further long-term studies focusing on liver histology as a primary endpoint are needed to confirm these effects.

SGLT2 inhibitorstype 2 diabetesnon-alcoholic fatty liver diseasedapagliflozin
مراجعةوصول مفتوح20251استشهاد· Semantic Scholar

Effectiveness of Self-Management of Blood Glucose in Improving Glycemic Control in Patients With Diabetes: A Systematic Review and Meta-Analysis

Cureus · مجلد 17 (12) · e99751-e99751

Self-monitoring of blood glucose (SMBG) is a widely used strategy in diabetes management, allowing patients to track their glucose levels and make informed decisions regarding diet, medication, and lifestyle adjustments. The effectiveness of SMBG remains debated. Structured SMBG, which involves systematic monitoring with clear guidance, has been suggested to provide greater benefits compared to unstructured SMBG. We aimed to evaluate the effectiveness of SMBG in improving glycemic control among diabetic patients. A systematic search was conducted in PubMed, the Cochrane Library, and Google Scholar. Studies were included if they examined SMBG interventions and reported glycated hemoglobin (HbA1c) as an outcome. Randomized controlled trials (RCTs) and observational studies were assessed for quality using the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale. Meta-analysis was performed using Review Manager (RevMan, The Cochrane Collaboration, Copenhagen, Denmark) to calculate mean differences (MD) and 95% confidence intervals (CI). The comprehensive database search yielded 7,667 records, of which 22 articles were selected for review and analysis. The meta-analysis of 22 studies showed that SMBG significantly reduced HbA1c levels compared to no SMBG (MD = -0.32%, 95% CI: -0.44% to -0.20%). Structured SMBG resulted in a greater reduction (MD = -0.25%, 95% CI: -0.41% to -0.09%) compared to unstructured SMBG. In summary, we showed that SMBG is effective in lowering HbA1c, particularly when structured protocols are followed. Healthcare providers should promote structured SMBG, along with patient education, to enhance adherence and optimize glycemic control. Further long-term studies are necessary to evaluate long-term benefits.

self-monitoring of blood glucoseglycemic controldiabetes mellitusHbA1c
مراجعةوصول مفتوح2025

Clinical Manifestations and Management of Prurigo in Pregnancy: A Systematic Review

Cureus · مجلد 17 (12) · e98216-e98216

A particular type of dermatosis known as prurigo of pregnancy (PP) is typified by highly itchy papulonodules that primarily affect the extremities' extensor surfaces and the hand and feet dorsum. Despite PP not being a rare illness, there is surprisingly a distinct lack of studies exploring its depth. Therefore, this study seeks to thoroughly describe the clinical manifestation and treatment of pregnancy-related prurigo. Additionally, it aims to provide a comprehensive and up-to-date assessment of the effectiveness of different approaches to pregnancy prurigo therapy. This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The systematic review searched PubMed, EMBASE, Web of Science, and Cochrane databases from the databases' establishment to 13 August 2024. The studies were deemed included if they were randomized controlled trials (RCTs), cohort studies, case-control, cross-sectional, case series, and case reports; if they reported clinical manifestations and treatment for PP; and if they were written in the English language. Studies were excluded if they did not meet the aforementioned inclusion criteria; moreover, they were excluded if they were of high risk of bias or low quality. The articles included were assessed using the Newcastle-Ottawa scale and methodological quality, and the synthesis of non-randomized studies. Four different studies, with a total of 63 patients, were included in our article. The typical rash of PP is described in most patients with variable onset and distribution on the body, from the extremities to the back to the buttocks. PP can be associated with a variety of conditions, including a history of other skin conditions, such as intrahepatic cholestasis and other medical conditions. Different treatments for PP in pregnant women were reported across the included studies, most commonly a combination of topical steroids, emollients, oral antihistamines, oral corticosteroids, and ultraviolet narrow band (UVB). The effectiveness of the various therapies is variable; some patients recover before delivery, while others recover months postpartum. This systematic review emphasizes how complicated PP is in terms of both its clinical manifestations, associations, and management. The evidence points to the urgent need for a more uniform approach to diagnosis and management due to substantial variability in the clinical features, onset, and treatment responses. The study emphasizes the need for additional, larger-scale research using standardized outcome measures to identify characteristics that predict treatment success and allow for more robust comparisons of treatment modalities.

prurigo of pregnancyprurigo nodularisprurituspregnancy